Quick Answer
Taysha Gene Therapies, Inc. reported Long Term Debt of $50.11 million for the year ending 2025.
- Taysha Gene Therapies, Inc. showed an increase of +14.0% in Long Term Debt from 2024 to 2025.
- This data is from Taysha Gene Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $27.81 million | Q1 2022: $37.39 million | Q2 2022: $37.58 million | Q3 2022: $37.77 million | Q1 2023: $38.16 million | Q2 2023: $38.35 million | Q3 2023: $38.55 million | Q1 2024: $40.51 million | Q2 2024: $37.84 million | Q3 2024: $42.97 million | Q1 2025: $42.45 million | Q2 2025: $41.05 million | Q3 2025: $50.85 million.
- Over the full 5 years of available data (2021 to 2025), Taysha Gene Therapies, Inc.'s Long Term Debt has grown by 34.7%.
- Historical annual values: Fiscal year 2025: $50.11 million | Fiscal year 2024: $43.94 million | Fiscal year 2023: $40.51 million | Fiscal year 2022: $37.97 million | Fiscal year 2021: $37.19 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: